Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: Reunite with members and non-members in the China actuarial community to discuss recent topics and related issues in areas such as macroeconomic sharing, IFRS 17, product strategy, cross-border communication and discussion, and more. Advance your career through learning and networking opportunities, and share your experiences in the finance and insurance industries, as well as other fields related to actuarial science.

Description: In this Determining Appropriate Sensitivity Tests webcast, explore sensitivity testing effectiveness, the important difference between sensitivity and stress testing and more. Understanding sensitivity testing is critical to actuarial work, especially in order to properly assess and evaluate risk factors. Come explore approached to sensitivity tests and effective evaluations of sensitivity test results in order to elevate your knowledge within the actuarial science field.

Description: The topics of ESG (Environmental, Social & Corporate Governance) and sustainability are an increasing area of focus for insurance companies, and thus actuaries. This webcast provides a primer on these topics along with considerations for US valuation actuaries and their evolution in European insurance markets.

Description: The ASU 2018-12 guidance, otherwise known as long-duration targeted improvements (LDTI), establishes a significant new category of benefit features called market risk benefits (MRB) that protect the contractholder from other-than-nominal capital market risk and expose the insurer to that risk. Insurers will have to measure market risk benefits at fair value. There are a few examples of MRB, Including the most common one— MGxBs on variable and indexed annuities. This change may bring significant volatility to earnings of these GMxB policies that are currently valued under the insurance accrual model (such as SOP 03-1). How to analyze the changes in volatility in MRBs became the natual question for many companies that haven't been valuing them on fair value basis. Besides the GMxBs, have you wondered when or if the guaranteed annuitization options offered by your company have other-than-norminal risk? By attending the session, you will: · Understand different types of MRBs. · Learn about ways to analyze the changes in volatility in MRBs from SOP 03-1. · Understand the accounting of MRB change for a contract under reinsurance going through spread and liability assumption updates. · Understand when the guaranteed annuitization options become MRB and how to evaluate that.

Description: Join us for the Pandemics & Paradigm Shifts: ERM in an Intensely Dynamic World panel discussion, where industry and regulatory perspectives will help provide insight into a number of topics. Expect interactive dialogue opportunities based on the conversation between the panelists and the audience. Key topics that will be conversed about, but the panel is not limited to, include a brief review of historical paradigm shifts and subsequent insurer failures, best practices and an outlook on the ultra-dynamic world of today and consideration of a company's enterprise risk management framework as it affects ratings and insurance department examinations.